Get the Stockscreener App
2.85
1.04%
-0.03
After Hours:
2.89
0.04
+1.40%
Cabaletta Bio Inc stock is traded at $2.85, with a volume of 1.96M.
It is down -1.04% in the last 24 hours and up +48.44% over the past month.
Cabaletta Bio Inc is a clinical-stage biotechnology company focused on the discovery and development of engineered T cell therapies and exploring their potential to provide a deep and durable, perhaps curative, treatment for patients with B cell-mediated autoimmune diseases. Its proprietary technology utilizes Chimeric AutoAntibody Receptor, or CAART cells, that are designed to selectively bind and eliminate only specific B cells that produce disease-causing autoantibodies, or pathogenic B cells, while sparing normal B cells. Its CABA platform encompasses two strategies: CARTA (chimeric antigen receptor T cells for autoimmunity) and CAART (chimeric autoantibody T cells) that have the potential to be applied across a broad range of autoimmune diseases.
See More
Previous Close:
$2.88
Open:
$2.85
24h Volume:
1.96M
Relative Volume:
0.77
Market Cap:
$260.68M
Revenue:
-
Net Income/Loss:
$-67.68M
P/E Ratio:
-1.7169
EPS:
-1.66
Net Cash Flow:
$-54.24M
1W Performance:
+22.84%
1M Performance:
+48.44%
6M Performance:
+159.09%
1Y Performance:
-41.24%
1-Day Range:
$2.77
$2.93
1-Week Range:
$2.24
$3.08
52-Week Range:
$0.9857
$5.46
Cabaletta Bio Inc Stock (CABA) Company Profile
Name
Cabaletta Bio Inc
Sector
Industry
Phone
(267) 759-3100
Address
2929 ARCH STREET, PHILADELPHIA, PA
Compare CABA with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
CABA
Cabaletta Bio Inc
|
2.85 | 263.42M | 0 | -67.68M | -54.24M | -1.66 |
|
VRTX
Vertex Pharmaceuticals Inc
|
416.81 | 104.76B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
481.67 | 63.06B | 2.46B | -319.09M | -52.09M | -2.4669 |
|
REGN
Regeneron Pharmaceuticals Inc
|
578.05 | 60.32B | 14.21B | 4.46B | 3.56B | 39.69 |
|
ARGX
Argen X Se Adr
|
843.66 | 51.55B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
165.76 | 34.49B | 398.11M | -1.03B | -868.57M | -5.7032 |
Cabaletta Bio Inc Stock (CABA) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Oct-10-25 | Resumed | Jefferies | Buy |
| Dec-20-24 | Downgrade | Evercore ISI | Outperform → In-line |
| Dec-19-24 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| Oct-10-24 | Initiated | UBS | Buy |
| Feb-05-24 | Initiated | Jefferies | Buy |
| Nov-29-23 | Initiated | William Blair | Outperform |
| Oct-24-23 | Initiated | Cantor Fitzgerald | Overweight |
| Oct-19-23 | Initiated | Stifel | Buy |
| Sep-05-23 | Initiated | Citigroup | Buy |
| Jul-18-23 | Initiated | Guggenheim | Buy |
| Jan-27-23 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Aug-30-22 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Dec-08-21 | Initiated | Wells Fargo | Overweight |
| Oct-19-21 | Resumed | Morgan Stanley | Overweight |
| Jun-30-21 | Initiated | Mizuho | Buy |
| Jan-08-21 | Initiated | Chardan Capital Markets | Buy |
| Oct-13-20 | Initiated | H.C. Wainwright | Buy |
| Nov-19-19 | Initiated | Cowen | Outperform |
| Nov-19-19 | Initiated | Evercore ISI | Outperform |
| Nov-19-19 | Initiated | Morgan Stanley | Overweight |
View All
Cabaletta Bio Inc Stock (CABA) Latest News
A activityJuly 2025 Update & High Conviction Trade Alerts - Trung tâm Dự báo KTTV quốc gia
Evaluating Cabaletta Bio Inc. with trendline analysisJuly 2025 PostEarnings & Risk Controlled Stock Pick Alerts - newser.com
Can Cabaletta Bio Inc. stock surprise with earnings upside2025 Price Targets & Daily Volume Surge Trade Alerts - Trung tâm Dự báo KTTV quốc gia
Cabaletta Bio Inc. stock trendline breakdownChart Signals & Consistent Profit Alerts - newser.com
Using flow based indicators on Cabaletta Bio Inc.2025 EndofYear Setup & Step-by-Step Swing Trade Plans - newser.com
Is Cabaletta Bio Inc a good long term investmentStock Watchlist Updates & Free Trading Psychology Coaching - earlytimes.in
Cabaletta Bio Inc. stock chart pattern explainedFed Meeting & Smart Money Movement Tracker - newser.com
Why Cabaletta Bio Inc. stock could rally in 2025July 2025 Review & Real-Time Chart Breakout Alerts - newser.com
How Cabaletta Bio Inc. stock reacts to bond yieldsTrade Exit Summary & Community Consensus Trade Signals - newser.com
Visualizing Cabaletta Bio Inc. stock with heatmapsMarket Weekly Review & Weekly Chart Analysis and Trade Guides - newser.com
Measuring Cabaletta Bio Inc.’s beta against major indices2025 Price Momentum & Verified Trade Idea Suggestions - newser.com
Can Cabaletta Bio Inc. hit a new high this monthVolume Spike & Real-Time Stock Price Movement Reports - newser.com
Advanced analytics toolkit walkthrough for Cabaletta Bio Inc.Watch List & Fast Entry Momentum Alerts - newser.com
Cabaletta Bio, Inc. Announces the Appointment of Steve Gavel as Chief Commercial Officer, Effective from October 14, 2025 - MarketScreener
Cabaletta Bio (CABA) Names Steve Gavel as Chief Commercial Officer - GuruFocus
Cabaletta Bio Announces Appointment of Steve Gavel as Chief Commercial Officer and Award of Inducement Grant - The Manila Times
275,000-option inducement: Cabaletta names Steve Gavel CCO to lead rese-cel strategy; BLA due 2027 - Stock Titan
Cabaletta Bio Presents Early Clinical Data From RESET-PV Trial Showing Rese-Cel Activity Without Preconditioning - MyChesCo
Cabaletta Bio Announces Public Offering of Common Stock and Warrants - MSN
Cabaletta Bio (CABA): Assessing Valuation After RESET-PV Trial Results Spark Investor Interest - Yahoo Finance
What candlestick patterns are forming on Cabaletta Bio Inc.2025 Dividend Review & Verified Entry Point Signals - newser.com
Tools to monitor Cabaletta Bio Inc. recovery probabilityEarnings Trend Report & Weekly Breakout Watchlists - newser.com
Cabaletta Bio (NASDAQ:CABA) Coverage Initiated by Analysts at Jefferies Financial Group - MarketBeat
Cabaletta Bio (NASDAQ:CABA) Given Buy Rating at HC Wainwright - MarketBeat
Jefferies resumes coverage on Cabaletta Bio stock with Buy rating By Investing.com - Investing.com Canada
Cabaletta Bio (CABA) Is Up 12.6% After CAR T Therapy Shows Early Success Without Preconditioning – Has the Bull Case Changed? - Yahoo Finance
Morning Market Movers: INTS, SHPH, CARM Spark Moves - RTTNews
Cabaletta Bio stock rating reiterated at Overweight by Cantor Fitzgerald - Investing.com Nigeria
HC Wainwright & Co. Reiterates Buy Rating for CABA with $16 Pric - GuruFocus
Jefferies resumes coverage on Cabaletta Bio stock with Buy rating - Investing.com
Can Cabaletta Bio Inc. stock outperform in 2025 bull marketJuly 2025 Recap & Expert Curated Trade Ideas - newser.com
Will Cabaletta Bio Inc. benefit from macro trendsWeekly Trend Report & Smart Swing Trading Alerts - newser.com
Cabaletta Bio Inc Stock (CABA) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.84%
0.50%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):